Citadel Advisors’s SomaLogic, Inc. Class A Common Stock SLGC Stock Holding History

Citadel Advisors’s Portfolio SLGC Stock Details SLGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-50,798	Closed	-$129K	–	15851
2023 Q4	$129K	Buy	+50,798	New	+$118K	﹤0.01%	10613
2023 Q3	–	Sell	-68,673	Closed	-$152K	–	15415
2023 Q2	$159K	Sell	68,673 -57,560	-46%	-$163K	﹤0.01%	10251
2023 Q1	$322K	Buy	126,233 +34,513	+38%	+$98.9K	﹤0.01%	9234
2022 Q4	$230K	Buy	91,720 +73,388	+400%	+$205K	﹤0.01%	9853
2022 Q3	$53K	Sell	18,332 -1,028,550	-98%	-$4.33M	﹤0.01%	11589
2022 Q2	$4.73M	Sell	1,046,882 -955,805	-48%	-$5.69M	﹤0.01%	3900
2022 Q1	$16.1M	Buy	2,002,687 +989,662	+98%	+$8.73M	﹤0.01%	2261
2021 Q4	$11.8M	Buy	1,013,025 +1,002,653	+9,667%	+$12M	﹤0.01%	2789
2021 Q3	$129K	Buy	+10,372	New	+$117K	﹤0.01%	12560

Citadel Advisors's SLGC Position: Q1 2024 in Review

Citadel Advisors sold out of SomaLogic, Inc. Class A Common Stock (SLGC) in Q1 2024, closing a stake of 50,798 shares — an estimated $129K sold.

Citadel Advisors first reported a position in SLGC in Q3 2021 and held it in 9 quarters. The position peaked at $16.1M in Q1 2022. 0 funds tracked by Wall St. Rank hold SLGC as of Q1 2024.

Citadel Advisors reported no remaining SomaLogic, Inc. Class A Common Stock position as of Q1 2024 after selling out during the quarter.
Citadel Advisors sold 50,798 SomaLogic, Inc. Class A Common Stock shares in Q1 2024, an estimated $129K.
Citadel Advisors first reported a position in SomaLogic, Inc. Class A Common Stock in Q3 2021 and held it in 9 quarters.
Citadel Advisors's SomaLogic, Inc. Class A Common Stock position peaked at $16.1M in Q1 2022.
0 funds tracked by Wall St. Rank held SomaLogic, Inc. Class A Common Stock as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.